Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy

被引：9
|
作者：
Mirza, Mansoor Raza
Monk, Bradley J.
Gil-Martin, Marta
Gilbert, Lucy
Canzler, Ulrich
Follana, Philippe
Waters, Justin S.
Kridelka, Frederic
Levy, Tally
Benigno, Benedict B.
Woie, Kathrine
Provencher, Diane M.
Lueck, Hans-Joachim
Herraez, Antonio Casado
Lesoin, Anne
Buscema, Joseph
Hellman, Kristina
Rimel, B. J.
Hazard, Sebastien
Matulonis, Ursula A.
机构：
[1] Nord Soc Gynecol Oncol NSGO, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[3] Univ Arizona, Coll Med, Arizona Oncol US Oncol Network, Phoenix, AZ USA
[4] Creighton Univ, Sch Med, St Josephs Hosp, Phoenix, AZ USA
[5] Grp Espanol Invest Canc Ovario GEICO, Barcelona, Spain
[6] IDIBELL, Catalan Inst Oncol, Barcelona, Spain
[7] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[8] AGO, Dresden, Germany
[9] Tech Univ Dresden, Dept Gynecol & Obstet, Dresden, Germany
[10] Ctr Antoine Lacassagne, Nice, France
[11] GINECO, Nice, France
[12] Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, England
[13] NCRI, Maidstone, Kent, England
[14] Domaine Univ Sart Tilman, CHU Liege, Liege, Belgium
[15] Belgium & Luxembourg Gynaecol Oncol Grp BGOG, Liege, Belgium
[16] Edith Wolfson Med Ctr, Holon, Israel
[17] ISGO, Holon, Israel
[18] Univ Gynecol Oncol, Atlanta, GA USA
[19] Univ Bergen, Bergen, Norway
[20] NSGO, Bergen, Norway
[21] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada
[22] Facharzt Frauenheilkunde Gynaekol Onkol P, Hannover, Germany
[23] HCS Carlos, Madrid, Spain
[24] Ctr Oscar Lambret, Dept Cancerol Senol, Lille, France
[25] GEICO, Lille, France
[26] Arizona Oncol Associates, Tucson, AZ USA
[27] Karolinska Univ Sjukhus, Stockholm, Sweden
[28] NSGO, Stockholm, Sweden
[29] Cedars Sinai Med Ctr, Hollywood, CA USA
[30] TESARO Inc, Waltham, MA USA
[31] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5517
引用
收藏
页数：5
相关论文
共 50 条
  • [21] The predictive value of homologous recombination deficiency (HRD) status for progression free survival (PFS) after first-line platinum-based chemotherapy in advanced ovarian cancer
    Xu, Y.
    Saverimuthu, A.
    Jadhav, A.
    Bhuiyan, R.
    Yio, J.
    Kumar, V.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 131 - 132
  • [22] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [23] Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer
    Kokabu, Tetsuya
    Tarumi, Yosuke
    Aoki, Kota
    Okamura, Ayaka
    Aoyama, Kohei
    Kataoka, Hisashi
    Yoriki, Kaori
    Mori, Taisuke
    CANCERS, 2024, 16 (15)
  • [24] Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment
    Ledermann, J. A.
    Oza, A. M.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J. I.
    Clamp, A. R.
    Scambia, G.
    Leary, A.
    Holloway, R. W.
    Amenedo Gancedo, M.
    Fong, P. C.
    Goh, J. C.
    O'Malley, D. M.
    Cameron, T.
    Maloney, L.
    Goble, S.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy
    Oza, A. M.
    Cibula, D.
    Oaknin, A.
    Poole, C.
    Mathijssen, R. H. J.
    Sonke, G. S.
    Colombo, N.
    Spacek, J.
    Vuylsteke, P.
    Hirte, H.
    Pfisterer, J.
    Plante, M.
    Hanker, L. C.
    Fielding, A.
    Haddad, V.
    Chmielecki, J.
    Friedlander, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 340 - 340
  • [26] Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial
    Brundage, M.
    Gropp, M.
    Mefti, F.
    Mann, K.
    Lund, B.
    Gebeski, V.
    Wolfram, G.
    Reed, N.
    Pignata, S.
    Ferrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Editorial Comment to Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab
    Matsumoto, Hiroaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 736 - 737
  • [28] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
    Vacheresse, Genevieve MacAulay
    Sabri, Elham
    Domingo, Sheryl
    Le, Tien
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
    Vacheresse, Genevieve Macaulay
    Le, Tien
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A194 - A194
  • [30] RESPONSE TO SUBSEQUENT PLATINUM-BASED CHEMOTHERAPY POST PARP INHIBITOR IN RECURRENT EPITHELIAL OVARIAN CANCER
    Vacheresse, Genevieve Macaulay
    Le, Tien
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A251 - A251
12345